$AMDA: is at 0.10 now which is close to it's 52 weeks low. The 52 week range is 0.09 and $1.12 . The FDA approval could be any day and their silicon nitride is already used in more than 20000 patients before it gets FDA approval. I think the risk at this level is real low, but the reward is much higher. If you are interested, see the following about this company.
http://investors.amedica.com/index.cfm
Amedica Corporation is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica markets spinal fusion products and is developing a new generation of orthopaedic bearings for hip and knee arthroplasty. The company operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and currently marketed in the U.S. and select markets in Europe and South America.
Amedica believes its silicon nitride technology platform enables it to offer new and transformative products in the orthopedic, and other medical device markets. Amedica believes they are the first and only company to use silicon nitride in medical applications, and over 20,000 of their silicon nitride spine products have been implanted in patients .
Amedica currently markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. The company believes its Valeo devices have a number of advantages over existing products due to silicon nitride’s key characteristics, resulting in faster and more effective fusion and reduced risk of infection. In addition to the silicon nitride-based spinal fusion products, Amedica also markets a complementary line of non-silicon nitride spinal fusion products, which allows the company to provide surgeons and hospitals with a broader range of products.
http://investors.amedica.com/index.cfm
Amedica Corporation is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica markets spinal fusion products and is developing a new generation of orthopaedic bearings for hip and knee arthroplasty. The company operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and currently marketed in the U.S. and select markets in Europe and South America.
Amedica believes its silicon nitride technology platform enables it to offer new and transformative products in the orthopedic, and other medical device markets. Amedica believes they are the first and only company to use silicon nitride in medical applications, and over 20,000 of their silicon nitride spine products have been implanted in patients .
Amedica currently markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. The company believes its Valeo devices have a number of advantages over existing products due to silicon nitride’s key characteristics, resulting in faster and more effective fusion and reduced risk of infection. In addition to the silicon nitride-based spinal fusion products, Amedica also markets a complementary line of non-silicon nitride spinal fusion products, which allows the company to provide surgeons and hospitals with a broader range of products.
